VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

[1]  D. Noh,et al.  Predictors of Axillary Node Metastases in Patients with T1 Breast Carcinoma , 1999 .

[2]  N. Ferrara.  Role of vascular endothelial growth factor in the regulation of angiogenesis. , 1999, Kidney international.

[3]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[5]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Isner,et al.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.

[7]  K. Alitalo,et al.  Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. , 1998, The American journal of pathology.

[8]  T. Pihlajaniemi,et al.  The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. , 1998, The American journal of pathology.

[9]  K. Alitalo,et al.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. , 1998, The American journal of pathology.

[10]  H. Gröne,et al.  Receptors of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in fetal and adult human kidney: localization and [125I]VEGF binding sites. , 1998, Journal of the American Society of Nephrology : JASN.

[11]  E. Tschachler,et al.  Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. , 1998, Cancer research.

[12]  F. Puglisi,et al.  Predictors of Axillary Lymph Node Metastases in Patients with T1 Breast Carcinoma , 1998, Cancer.

[13]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  K. Alitalo,et al.  VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. , 1997, Developmental biology.

[15]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[16]  U. Weidle,et al.  Lack of lymphangiogenesis in human primary cutaneous melanoma. Consequences for the mechanism of lymphatic dissemination. , 1997, The American journal of pathology.

[17]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[18]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[19]  R. Jain,et al.  Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. , 1997, Microvascular research.

[20]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[21]  S. Fox,et al.  TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.

[22]  M. Shibuya,et al.  Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[23]  H. Dvorak,et al.  The vesiculo‐vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation , 1996, Journal of leukocyte biology.

[24]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Hanselaar,et al.  A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[26]  A. Harris,et al.  Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Alitalo,et al.  Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. , 1994, Oncogene.

[28]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[29]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[30]  R K Jain,et al.  Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.

[31]  O'Morchoe Pj,et al.  DIFFERENCES IN LYMPHATIC AND BLOOD CAPILLARY PERMEABILIITY ULTRASTRUCTURAL- FUNCTIONAL CORRELATIONS , 1987 .

[32]  L. Leak.  Electron microscopic observations on lymphatic capillaries and the structural components of the connective tissue-lymph interface. , 1970, Microvascular research.

[33]  M. Laberge.  [Cancer of the breast]. , 1961, Laval medical.

[34]  N. Ferrara,et al.  Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis , 1999 .

[35]  K. Alitalo,et al.  VEGF-B binds to VEGFR-1 and regulates plasminogen activator activity in endothelial cells , 1998 .

[36]  T. Pihlajaniemi,et al.  Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. , 1998, Matrix biology : journal of the International Society for Matrix Biology.

[37]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. , 1996, The EMBO journal.

[38]  M. Shibuya.  Role of VEGF-flt receptor system in normal and tumor angiogenesis. , 1995, Advances in cancer research.

[39]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[40]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[41]  C. C. O'morchoe,et al.  Differences in lymphatic and blood capillary permeability: ultrastructural-functional correlations. , 1987, Lymphology.

[42]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .